2011年6月22日 · One frequently reads that an adverse effect may occur if a certain drug is given to someone who is already taking cyp3a inhibitors or inducers. Answer this question The …

2025年2月3日 · Avoid using this medicine with strong or moderate CYP3A inducers. CYP3A substrates: If Journavx is used together with sensitive CYP3A substrates or CYP3A substrates …

Adverse Reactions with Concomitant Use with CYP3A Inhibitors: Concomitant use with strong or moderate CYP3A inhibitors increased vanzacaftor, tezacaftor, and deutivacaftor exposure, …

2025年2月10日 · Concomitant use of potent CYP3A inducers that can significantly reduce nirmatrelvir or ritonavir plasma concentrations and result in potential loss of virologic response …

2024年5月10日 · If concomitant use of a moderate CYP3A inhibitor cannot be avoided, reduce olaparib dosage to 150 mg twice daily. If concomitant use of CYP3A inhibitor is discontinued, …

2 天之前 · Easy-to-read patient tips for valacyclovir covering how it works, benefits, risks, and best practices.

2024年11月25日 · While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of ATTRUBY with UGT inducers and …

2024年3月12日 · Use of CERDELGA is contraindicated, to be avoided, or requires dosage adjustment in patients taking CYP2D6 or CYP3A inhibitors, depending on CYP2D6 …

2024年11月10日 · Avoid concomitant use of TUKYSA with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is …

2025年3月10日 · Cautions for Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Contraindications. Concomitant use with drugs highly dependent on CYP3A for metabolism …